More affordable Zepbound? Lilly’s new pricing plan shakes up obesity treatment

Pallavi Madhiraju- February 26, 2025 0

Eli Lilly and Company (Lilly) has introduced new single-dose vials of Zepbound (tirzepatide), expanding treatment options for self-pay patients seeking obesity medications. The company’s latest ... Read More

Eli Lilly acquires Organovo’s FXR program to advance IBD drug development

Pallavi Madhiraju- February 25, 2025 0

In a significant industry development, Eli Lilly and Company has acquired Organovo Holdings, Inc.’s FXR program, including its lead drug candidate FXR314, marking a major ... Read More

Eli Lilly sets 2024 revenue at $45bn amid revised guidance

Pallavi Madhiraju- January 15, 2025 0

Eli Lilly and Company, a leading global pharmaceutical firm, has adjusted its 2024 revenue forecast to $45 billion, marking a 32% increase from the previous ... Read More

Eli Lilly acquires promising PI3Kα inhibitor from Scorpion Therapeutics

Pallavi Madhiraju- January 15, 2025 0

Eli Lilly and Company (Lilly) has announced a significant acquisition of Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program, a move poised to enhance its oncology portfolio. ... Read More

Eli Lilly achieves breakthrough with Imlunestrant in Phase 3 breast cancer trial

Pallavi Madhiraju- December 11, 2024 0

Eli Lilly and Company has announced encouraging results from its Phase 3 EMBER-3 study evaluating imlunestrant, an investigational oral selective estrogen receptor degrader (SERD), for ... Read More

Lilly commits $3bn to Wisconsin facility to boost injectable medicine production

Pallavi Madhiraju- December 6, 2024 0

Eli Lilly and Company (Lilly) has unveiled plans for a $3 billion expansion of its newly acquired manufacturing facility in Kenosha County, Wisconsin, signalling a ... Read More

Lilly’s Phase 3 EMBER-3 trial results set to shake up breast cancer treatment landscape

Pallavi Madhiraju- November 4, 2024 0

Eli Lilly and Company (NYSE: LLY) announced it will present data from its Phase 3 EMBER-3 trial for imlunestrant, an oral selective estrogen receptor degrader ... Read More

Lilly launches $4.5bn medicine foundry to reshape drug production and clinical trials

Pallavi Madhiraju- October 3, 2024 0

Eli Lilly and Company has committed $4.5 billion to establish a revolutionary facility in Lebanon, Indiana—the Lilly Medicine Foundry. This one-of-a-kind site is set to ... Read More

Eli Lilly’s once-weekly insulin efsitora alfa matches daily insulin for A1C reduction, boosts stock interest

Pallavi Madhiraju- September 12, 2024 0

Eli Lilly and Company (NYSE: LLY) announced results from its QWINT-5 phase 3 trial, demonstrating that its once-weekly insulin efsitora alfa offers a comparable reduction ... Read More

Organon and Eli Lilly expand global reach of migraine treatment Emgality

Pallavi Madhiraju- August 21, 2024 0

Organon and Eli Lilly and Company have expanded their commercialization agreement for Emgality, a leading migraine treatment, into 11 additional markets, reinforcing their commitment to ... Read More

1234...1020 / 94 Posts